Nexcella, a subsidiary of Immix Biopharma, announced that an editorial written by Maria Sjostrand and Michel Sadelain of Memorial Sloan Kettering Cancer Center was published 2023 in Haematologica highlighting NXC-201 in the context of the current U.S. Food And Drug Administration, FDA, approved BCMA CAR-T Cell therapies. "The study shows a good safety profile, overall similar to other BCMA CAR T cell phase I-II studies, and similar efficacy, albeit with shorter follow-up, to that initially reported with the later FDA-approved BCMA CAR T cells," the authors Maria Sjostrand and Michel Sadelain stated. The "trial included nine patients who had relapsed after treatment with an anti-BCMA antibody, belantamab mafodotin, prior to receiving HBI0101, which the authors suggested may be associated with a less favorable response to CAR therapy."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMMX:
- Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
- Immix Biopharma’s Nexcella announces NXC-201 clinical data
- Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
- Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
- Nexcella treats 50 patients with CAR-T NXC-201 in Phase 1b/2a trial
